8-K 1 dotronix044934_8k.htm Dottronix, Inc. Form 8-K dated October 19, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d)
Of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 19, 2004

DOTRONIX, INC.
(Exact Name of Registrant as Specified in its Charter)

Minnesota
(State or Other Jurisdiction of Incorporation)

0-9996 41-1387074
(Commission File Number) (IRS Employer
  Identification No.)

160 First Street S.E.
New Brighton, Minnesota 55112-7894

(Address of Principal Executive Offices) (Zip Code)

(651) 633 1742
(Registrant’s Telephone Number, Including Area Code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 8.01.  Other Events.

        On October 19, 2004, Dotronix, Inc. issued a press release announcing that it would hold its annual shareholders meeting on Tuesday, December 8, 2004. Proxy statements are expected to be mailed on or about November 5, 2004 to its shareholders of record on October 28, 2004.

Item 9.01.  Financial Statements and Exhibits.

            (a)       Financial statements: None.

            (b)       Pro forma financial information: None.

            (c)       Exhibits:

                        99.1    Press Release dated October 19, 2004



SIGNATURE

        Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 19, 2004

DOTRONIX, INC.
         
  
  By  /s/ Robert V. Kling 

    Robert V. Kling 
    Chief Financial Officer